Dexcom Inc
NASDAQ:DXCM
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
54.84
90.75
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
DXCM
stock under the Base Case scenario is
58.75
USD.
Compared to the current market price of 66.96 USD,
Dexcom Inc
is
Overvalued by 12%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Dexcom Inc.
| US |
|
Abbott Laboratories
NYSE:ABT
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Dexcom’s dominant position in continuous glucose monitoring faces mounting pressure from Abbott’s Freestyle Libre, which offers lower-cost options and wider distribution, potentially diluting Dexcom’s market share and pricing power.
Heightened reimbursement scrutiny might compress Dexcom’s margins; insurers could demand more cost-effective offerings, forcing the company to lower sensor prices or risk losing coverage status.
Failure to outpace competitor innovation may erode Dexcom’s technological advantage if rivals release superior long-wear or more seamless CGM solutions, undermining the brand’s leadership position.
Dexcom’s recognized best-in-class accuracy and brand loyalty in Type 1 diabetes management could preserve its premium pricing and reinforce market leadership despite competitive threats.
The newly launched G7 system, significantly smaller and easier to use, has the potential to accelerate adoption in less-penetrated Type 2 diabetic segments and bolster strategic partnerships with insulin pump manufacturers.
Geographic expansion and growing acceptance of CGM in international markets should diversify Dexcom’s revenue base, mitigating reliance on the U.S. and fueling long-term top-line growth.
Revenue & Expenses Breakdown
Dexcom Inc
Balance Sheet Decomposition
Dexcom Inc
| Current Assets | 5.2B |
| Cash & Short-Term Investments | 3.3B |
| Receivables | 1.2B |
| Other Current Assets | 739.2m |
| Non-Current Assets | 2.3B |
| PP&E | 1.5B |
| Intangibles | 103.1m |
| Other Non-Current Assets | 652.1m |
| Current Liabilities | 3.3B |
| Accounts Payable | 451.5m |
| Accrued Liabilities | 1.7B |
| Other Current Liabilities | 1.2B |
| Non-Current Liabilities | 1.4B |
| Long-Term Debt | 1.3B |
| Other Non-Current Liabilities | 143.4m |
Free Cash Flow Analysis
Dexcom Inc
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Dexcom Inc
|
Revenue
|
4.5B
USD
|
|
Cost of Revenue
|
-1.8B
USD
|
|
Gross Profit
|
2.7B
USD
|
|
Operating Expenses
|
-1.9B
USD
|
|
Operating Income
|
777.7m
USD
|
|
Other Expenses
|
-57m
USD
|
|
Net Income
|
720.7m
USD
|
DXCM Profitability Score
Profitability Due Diligence
Dexcom Inc's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
Score
Dexcom Inc's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
DXCM Solvency Score
Solvency Due Diligence
Dexcom Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.
Score
Dexcom Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DXCM Price Targets Summary
Dexcom Inc
According to Wall Street analysts, the average 1-year price target for
DXCM
is 88.06 USD
with a low forecast of 68.68 USD and a high forecast of 117.6 USD.
Dividends
Current shareholder yield for
DXCM is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
DXCM
stock under the Base Case scenario is
58.75
USD.
Compared to the current market price of 66.96 USD,
Dexcom Inc
is
Overvalued by 12%.